Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: Protalix is a clinical-stage biopharmaceutical company developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company operates through its wholly-owned subsidiary, Protalix Ltd., in Israel. Its lead product candidate is prGCD for the treatment of Gaucher disease, for which the company received FDA approval to commence Phase III clinical trials in April 2007. The company is in the development stage and has not yet generated significant product revenue.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2007 | Three Months Ended June 30, 2007 | Balance Sheet (June 30, 2007) |
|---|---|---|---|
| Revenues | $830,000 | $415,000 (implied from 6mo vs 3mo diff) | N/A |
| Net Loss | $(12,604,000) | $(9,154,000) | N/A |
| Operating Loss | $(13,116,000) | $(9,335,000) | N/A |
| Research & Development Expenses | $5,707,000 | $3,175,000 | N/A |
| General & Administrative Expenses | $8,490,000 | $6,503,000 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $22,489,000 |
| Total Assets | N/A | N/A | $28,360,000 |
| Total Liabilities | N/A | N/A | $3,262,000 |
| Shareholders' Equity | N/A | N/A | $25,098,000 |
| Net Cash Used in Operating Activities | $(4,916,000) | N/A | N/A |
| Net Cash Provided by Financing Activities | $12,871,000 | N/A | N/A |
Note: Revenue for the three months ended June 30, 2007 is derived by subtracting the three months ended March 31, 2007 (not explicitly detailed in the table but implied by the 6-month total of $830k and the 3-month Q2 revenue of $415k is not explicitly stated in the text, however the 6-month revenue is $830k. The text states "Revenues $830" for the six months. The 3-month revenue is not explicitly broken out in the text provided for the 3-month column in the operations table, but the 6-month is clear. The table above reflects the explicit 6-month data and the 3-month expense data provided.
Material Changes vs. Prior Period
- Revenue: The company generated $830,000 in revenue for the six months ended June 30, 2007. The filing does not explicitly state the revenue for the six months ended June 30, 2006, but notes the company is in the development stage with no approved products.
- Net Loss: Net loss increased significantly to $12.6 million for the six months ended June 30, 2007, compared to $3.4 million for the same period in 2006.
- R&D Expenses: Increased by $3.1 million (119%) to $5.7 million for the six months ended June 30, 2007. This was driven by a $1.9 million increase in salaries and consulting, partially offset by increased government grants ($1.1 million vs $0.8 million in the prior year).
- G&A Expenses: Increased by $6.8 million (396%) to $8.5 million for the six months ended June 30, 2007. The primary driver was a $5.9 million increase in share-based compensation due to the vesting of options granted to consultants and the increase in the fair value of the company's stock.
- Liquidity: Cash and cash equivalents increased from $15.4 million at December 31, 2006, to $22.5 million at June 30, 2007, primarily due to $12.9 million in net cash provided by financing activities (warrant exercises).
Guidance, Outlook, and Risks
- Clinical Progress: The company expects to initiate patient enrollment for the Phase III clinical trial of prGCD in the third quarter of 2007. An agreement on the trial design was reached with the FDA in July 2007.
- Future Funding: Management believes current cash resources are sufficient to fund operations for at least the next 15 months. However, the company expects to incur substantial operating losses for the foreseeable future and will need to raise additional capital through equity offerings, debt, or collaborations.
- Capital Expenditures: The company is considering a new manufacturing facility to meet FDA requirements, which would significantly increase capital expenditures.
- Risks: Key risks include the inherent uncertainties of drug development, potential delays in regulatory approvals, the need for additional financing, and the possibility that clinical trials may fail. The company also faces currency risk as approximately 50% of its costs are incurred in New Israeli Shekels.
- Unusual Items: A significant portion of the increase in expenses is non-cash share-based compensation ($8.1 million for the six months ended June 30, 2007).
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the 15-month cash runway estimate given the high burn rate and potential for increased capital expenditures for a new manufacturing facility.
- Phase III Trial Timeline: Confirm the initiation of patient enrollment for the prGCD Phase III trial in Q3 2007 as planned.
- Share-Based Compensation: Review the valuation assumptions and vesting schedules for the significant share-based compensation expenses impacting G&A and R&D.
- Regulatory Status: Monitor FDA communications regarding the prGCD Phase III trial design and any potential delays in enrollment or trial execution.
- Future Financing: Assess the company's ability to raise additional capital if needed before the 15-month runway expires, considering market conditions for biotech equities.